Arcoxia has shown significantly master efficacy.

At a recent Merck individual briefing about etoricoxib, Dr Herbert Baraf (Center for Rheumatology and Bone Investigating, Wheaton, MD) noted that it is the only drug so far to have show fighter efficacy to a traditional nonsteroidal anti-inflammatory drug (NSAID) in 2 of these indications
This is a part of article Arcoxia has shown significantly master efficacy. Taken from "Etoricoxib Arcoxia" Information Blog